UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 5, 2004
TRIMERIS, INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 0-23155 | 56-1808663 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 3518 Westgate Drive, Suite 300, Durham, North Carolina | 27707 | |||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 419-6050
N/A
(Former Name or Former Address, if Changed Since Last Report)
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
| Exhibit No. | ||
| 99.1 | Transcript of conference call held January 5, 2004. |
ITEM 9. REGULATION FD DISCLOSURE
The following information is being furnished pursuant to Regulation FD.
On January 5, 2004, Trimeris, Inc. held a conference call and webcast to announce the extension of the research agreement with Roche and to update the status of the T-1249 development program. A transcript of this conference call is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Trimeris Safe Harbor Statement
The Private Securities Litigation Reform Act of 1995 (the “Act”) provides a “safe harbor” for forward-looking statements. This document and any attachments may contain forward-looking information about the Company’s financial results and business prospects that involve substantial risks and uncertainties. These statements can be identified by the fact that they use words such as “expect,” “project,” “anticipate”, “intend,” “plan,” “believe” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially are the following: there is uncertainty regarding the success of research and development activities, regulatory authorizations and product commercializations; the results of our previous clinical trials are not necessarily indicative of future clinical trials; and, our drug candidates are based upon novel technology, are difficult and expensive to manufacture and may cause unexpected side effects. For a detailed description of these factors, see Trimeris’ Form 10-K filed with the Securities and Exchange Commission on March 27, 2003 and its periodic reports filed with the SEC.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRIMERIS, INC.
| ||
| By: | /s/ Dani P. Bolognesi | |
| Dani P. Bolognesi | ||
| Chief Executive Officer and | ||
| Chief Scientific Officer | ||
Dated January 7, 2004
